Effects of antibiotic therapy on Pseudomonas aeruginosa-induced lung injury in a rat model

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 10, 1999, Pages 2389-2394

  Ernst, Erika J ^a   Hashimoto, Satoru ^b   Guglielmo, Joseph ^c   Sawa, Teiji ^d   Pittet, Jean Francois ^d   Kropp, Helmut ^e   Jackson, Jesse J ^e   Wiener Kronish, Jeanine P ^d  

^a UNIVERSITY OF IOWA   (United States)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; CILASTATIN PLUS IMIPENEM;

ANIMAL EXPERIMENT; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL PNEUMONIA; DRUG EFFECT; DRUG POTENCY; GRAM NEGATIVE INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LUNG INJURY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RAT;

EID: 0032841476     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.10.2389     Document Type: Article

References (30)

1. Allen, K. D., and H. T. Green. 1989. Aztreonam in infections due to aerobic gram-negative bacteria. J. Antimicrob. Chemother. 23:290-291.
2. Bahrami, S., H. Redl, W. A. Buurman, and G. Schlag. 1992. Influence of the xanthine derivative HWA 138 on endotoxin-related coagulation disturbances: effects in non-sensitized vs. D-galactosamine sensitized rats. Thromb. Haemost. 68:418-423.
3. Barza, M. 1985. Imipenem: first of a new class of beta-lactam antibiotics. Ann. Intern. Med. 103:552-560.
4. Birnbaum, J. F., M. Kahan, H. Kropp, and J. S. MacDonald. 1987. Carbapenems, a new class of beta-lactam antibiotics. Discovery and development of imipenem/cilastatin. Am. J. Med. 78:3-21.
5. Boccazzi, A., M. Langer, M. Mandeli, A. M. Ranzi, and R. Urso. 1989. The pharmacokinetics of aztreonam and penetration into the bronchial secretions of critically ill patients. J. Antimicrob. Chemother. 23:401-407.
6. Brewer, S. C., R. G. Wunderink, C. B. Jones, and K. V. Leeper, Jr. 1996. Ventilator-associated pneumonia due to Pseudomonas aeruginosa. Chest 109:1019-1029.
7. Brogden, R. N., and R. C. Heel. 1986. Aztreonam, a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 31:96-130.
8. Buckley, M. M., R. N. Brogden, L. B. Barradell, and K. L. Goa. 1992. Imipenem/cilastatin, a reappraisal of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 44:408-444.
9. Craven, D. E., and K. Steger. 1996. Nosocomial pneumonia in mechanically ventilated adult patients: epidemiology and prevention in 1996. Semin. Respir. Infect. 11:32-53.
10. Cullmann, W., K. H. Buscher, and W. Dick. 1987. Selection and properties of Pseudomonas aeruginosa variants resistant to beta-lactam antibiotics. Eur. J. Clin. Microbiol. 6:467-473.
11. Demaria, A., T. L. Treadwell, C. A. Saunders, R. Porat, and W. R. McCabe. 1989. Randomized clinical trial of aztreonam and aminoglycoside antibiotics in the treatment of serious infections caused by gram-negative bacilli. Antimicrob. Agents Chemother. 33:1137-1143.
12. Dofferhoff, A. S. M., J. H. Poland, H. G. de Vries-Hispers, P. O. M. Mulder, J. Veits, and V. J. Bom. 1991. Effects of different types and combinations of antimicrobial agents on endotoxin release from gram-negative bacteria: an in-vitro and in-vivo study. Scand. J. Infect. Dis. 23:745-754.
13. Fabregas, N., A. Torres, M. El-Ebiary, J. Ramfrez, C. Hernandez, J. Gonzalez, J. P. de la Bellacasa, J. de Anta, and R. Rodoriguez-Roisin. 1996. Histopathologic and microbiologic aspects of ventilator-associated pneumonia. Anesthesiology 84:760-771.
14. Fagon, J. Y., J. Chastre, A. J. Hance, P. Montravers, A. Novara, and C. Gilbert. 1993. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am. J. Med. 94:281-288.
15. Galanos, C., and M. A. Freudenberg. 1993. Mechanisms of endotoxin shock and endotoxin hypersensitivity. Immunobiology 87:346-356.
16. Galanos, C., M. A. Freudenberg, and W. Reutter. 1979. Galactosamine-induced sensitization to the lethal effects of endotoxin. Proc. Natl. Acad. Sci. USA 76:5939-5943.
17. Hashimoto, S., E. Wolfe, B. Guglielmo, R. Shanks, J. Sundelof, J. F. Pittet, E. Thomas, and J. Wiener-Kronish. 1996. Aerosolization of imipenem/cilastatin prevents pseudomonas-induced acute lung injury. J. Antimicrob. Chemother. 38:809-818.
18. Jackson, J. J., and H. Kropp. 1992. β-Lactam antibiotic-induced release of free endotoxin: in vitro comparison of penicillin-binding protein (PBP) 2-specific imipenem and PBP-3-specific ceftazidime. J. Infect. Dis. 165:1033-1041.
19. 14C]aztreonam in rats, dogs, and monkeys. Antimicrob. Agents Chemother. 26:119-126.
20. Kudoh, I., J. P. Wiener-Kronish, S. Hashimoto, J.-F. Pittet, and D. Frank. 1994. Exoproduct secretions of Pseudomonas aeruginosa strains influence severity of alveolar injury. Am. J. Physiol. 267:L511-L516.
21. National Committee for Clinical Laboratory Standards. 1997. Methods for determining dilution antimicrobial susceptibility tests for bacteria that grow aerobically. M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa.
22. Parrillo, J. E., M. M. Parker, C. Nathanson, A. F. Suffredini, R. L. Danner, R. E. Cunnion, and F. P. Ognibene. 1990. Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction and therapy. Ann. Intern. Med. 113:227-237.
23. Rouby, J. J. 1996. Nosocomial infection in the critically ill. The lung as a target organ. Anesthesiology 84:757-758.
24. Sawa, T., K. Kurahashi, M. Ohara, M. A. Gropper, V. Doshi, J. W. Larrick, and J. P. Wiener-Kronish. 1998. Evaluation of antimicrobial and lipopolysaccharide-neutralizing effects of a synthetic CAP18 fragment against Pseudomonas aeruginosa in a mouse model. Antimicrob. Agents Chemother. 42: 3269-3275.
25. Shenep, J. L., R. P. Barton, and K. A. Mogan. 1985. Role of antibiotic class in the rate of liberation of endotoxin during therapy for experimental gramnegative bacterial sepsis. J. Infect. Dis. 151:1012-1018.
26. Stradvik, G., A. S. Malmborg, T. Bergan, H. Michalsen, O. T. Storrosten, and B. Wretlind. 1988. Imipenem/cilastatin, an alternative treatment of Pseudomonas infection in cystic fibrosis. J. Antimicrob. Chemother. 21:471-480.
27. Taylor, G. D., M. Buchanan-Chell, T. Kirkland, M. McKenzie, and R. Wiens. 1994. Bacteremic nosocomial pneumonia. A 7-year experience in one institution. Chest 108:785-788.
28. Torres, A., R. Aznar, J. M. Gatell, P. Jimenez, J. Gonzalez, A. Ferrer, R. Celis, and R. Rodriguez-Roisin. 1990. Incidence, risk, and prognosis factors of nosocomial pneumonia in mechanically ventilated patients. Am. Rev. Respir. Dis. 142:523-528.
29. Wiener-Kronish, J. P., K. H. Albertine, and M. A. Matthay. 1991. Differential responses of the endothelial and epithelial barriers of the lung in sheep to Escherichia coli endotoxin. J. Clin. Investig. 88:864-875.
30. Wiener-Kronish, J. P., T. Sakuma, I. Kudoh, J.-F. Pittet, D. Frank, L. Dobbs, M. L. Vasil, and M. Matthay. 1993. Alveolar epithelial injury and pleural empyema in acute P. aeruginosa pneumonia in anesthetized rabbits. J. Appl. Physiol. 75:1661-1669.